PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 25 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel,

Katherine E. Henderson

Serial No. Filed

: 10/691.923

For

: October 23, 2003

: METHODS FOR TREATING VIRAL INFECTION USING IL-28

AND IL-29

Examiner

: Hamud, F. · 1647

Art Unit Docket No.

: 02-24

Date

: October 25, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir

The Restriction Requirement mailed September 26, 2005, has been received and reviewed.

The Office Action sets forth a restriction requirement under 35 USC §121. Applicants were requested to elect one of twelve designated groups as briefly noted below:

- T. Claims 1-9, 18, 23-25, 33, 38-39, 47 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:2, classified in class 424, subclass 85.2.
- Claims 1-9, 19, 23-25, 34, 38-39, 48 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEO ID NO:18, classified in class 424, subclass 85.2.

Response to Restriction Requirement Applicants: Klucher et al.

Serial No.: 10/691,923 Filed: October 23, 2003

For: METHODS FOR TREATING VIRAL INFECTIONS USING IL-28 AND IL-29

- III. Claims 1-9, 20, 23-25, 35, 38-39, 49 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:24. classified in class 424, subclass 85.2.
- IV. Claims 1-9, 20, 23-25, 35, 38-39, 49 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:26, classified in class 424, subclass 85.2.
- V. Claims 1-9, 21, 23-25, 36, 38-39, 50 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:28, classified in class 424, subclass 85.2.
- VI. Claims 1-9, 21, 23-25, 36, 38-39, 50 and 52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID N0:30, classified in class 424, subclass 85.2.
- VII. Claims 1-9, 22-25, 37-39 and 51-52, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:36, classified in class 424, subclass 85.2.
- VIII. Claims 10-17, 26, 30-32, 40, 44-46, 53 and 57-61, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:4, classified in class 424, subclass 85.2.
- IX. Claims 10-17, 27, 30-32, 41, 44-46, 54 and 57-61, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEO ID NO:20, classified in class 424, subclass 85.2.
- X. Claims 10-17, 28, 30-32, 42, 44-46, 55 and 57-61, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEO ID NO:32, classified in class 424, subclass 85.2.
- XI. Claims 10-17, 28, 30-32, 42, 44-46, 55 and 57-61, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEO ID NO:34, classified in class 424, subclass 85.2.
- XII. Claims 10-17, 29-32, 43-46 and 56-61, 10-17, 28, 30-32, 42, 44-46, 55 and 57-61, drawn to a method of treating a viral infection, by administering an effective amount of the polypeptide of SEQ ID NO:38, classified in class 424, subclass 85.2.

Response to Restriction Requirement

Applicants: Klucher et al. Serial No.: 10/691,923 Filed: October 23, 2003

For: METHODS FOR TREATING VIRAL INFECTIONS USING IL-28 AND IL-29

In response to the Requirement for Restriction Election, Applicants elect Group XI, claims 10-17, 28, 30-32, 42, 44-46, 55 and 57-61 (claims 62-66 as amended per the accompanying Preliminary Amendment), drawn to a method of treating a viral infection by administering an effective amount of the polypeptide of SEQ ID NO:34, without traverse. Applicants reserve the right to pursue examination of the non-elected claims in continuation or divisional applications.

Early reconsideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6540.

Respectfully Submitted,

Brian J. Walsh Registration No. 45,543

Enclosures:

Preliminary Amendment Amendment Fee Transmittal (in duplicate) Supplemental IDS Postcard

ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle, Washington 98102